Glenview's Robbins Happy With $207 Share Offer by CVS for Aetna
(Bloomberg) -- Larry Robbins, whose hedge fund Glenview Capital Management is a major holder of Aetna Inc., said he was pleased with CVS Health Corp.'s offer to buy the health insurer.
“This seems like a fair price,” Robbins, founder of the $11.7 billion firm, said about the $207 a share offer. “It is an attractive deal for both sides.”
CVS agreed to buy Aetna Sunday in a mix of cash and stock. Robbins said the combined companies could be worth between $105 to $120 a share within one to two years, not including any potential gain from tax reform. CVS shares traded for $71.97, down 4.2 percent at 2:55 pm. Aetna was at $179.56, down 1 percent.
“Investors today are making a mistake by undervaluing CVS, much the way they undervalued Aetna in 2013,” he said in a telephone interview.
Glenview bought Aetna shares in the fourth quarter of 2013, when the stock sold for an average price of about $65. The CVS offer is roughly three times what Robbins initially paid.
Glenview held 3.8 million Aetna shares as of Sept. 30, according to the latest data compiled by Bloomberg. Assuming the hedge fund still holds the same position, its stake would be worth about $785 million using the $207-a-share offer, if the deal closes.
Robbins has long been a fan of health-care stocks. His hedge fund had 46 percent of its U.S. equity holdings in that sector as of Sept. 30.
Read more on the CVS-Aetna deal here
To contact the reporter on this story: Charles Stein in Boston at cstein4@bloomberg.net.
To contact the editors responsible for this story: Margaret Collins at mcollins45@bloomberg.net, Josh Friedman
©2017 Bloomberg L.P.
-
Navigating Friction And Energy Realities: An Analysis Of Marco Rubio's October Visit To India
Occurring at a critical juncture marked by stalled trade negotiations and escalating geopolitical pressures over global energy supplies, the visit offers a profound window into modern US-India relations.
-
India Exports Capital. Why Not Export Trusteeship?
The big question, then, is whether India can build an institution that global borrowers, investors, banks, and lawyers can trust, even without an Indian connection.
-
France's Economy & Politics Are In Crisis | The Reason Why
Let's look at how the French economy and politics evolved under Nicolas Sarkozy, Franois Hollande and Emmanuel Macron.
-
You May Inherit The Business. You Must Earn Its Credibility.
Succession tests the founder's ability to share authority as much as it tests the next generation's readiness to assume it.
-
Signing Deals Is One Thing; Making Them Work Is Another | The Week In Whys
Sometimes, things don't turn out as planned. Indian companies have lost some bids to rivals, some projects won't produce until 2030.
-
FOMC Wall, PERM Suspension, Hospital Stocks | Talking Points This Week
A PERM suspension would directly affect green-card sponsorship rather than H-1B visas, so the near-term earnings impact could remain relatively limited. The key question is whether this marks a new phase in US scrutiny of Indian IT.
-
Everything, Everywhere, All At Once: Dalal Street's Week To Forget | Joining The Dots
Visa curbs, a Starlink spat and cancer drug caps: what connects this week's shocks for Indian markets
-
India Is Going Abroad For Critical Minerals. But It May Take Years To Pay Off | The Reason Why
Although India's steps are in the right direction, they remain modest compared with India's growing dependence.
-
When Everyone Has AI, What Gives You An Edge?
India's young workforce is entering an uncertain world of work where powerful AI tools are becoming widely accessible. The advantage will belong to those who combine deep expertise with digital fluency, and the distinctly human capabilities that technology cannot manufacture.
-
Wrong Labels, High Pesticide Residues Holding Back Agri Exports | The Reason Why
India needs stronger domestic food-safety and labelling standards, with best practices becoming part of everyday business for farmers, traders and food companies.
